大行評級|大摩:下調華虹半導體目標價至26港元 評級“增持”
摩根士丹利發表報吿指,華虹半導體第二季業績符合預期,營收為4.79億美元,按季增長4%,按年減少24%;毛利率為10.5%,符合指引;整體產能利用率達到98%,明顯好過第一季的92%。該行將其目標價由28港元降至26港元,評級“增持”。
大摩指,華虹管理層在業績會議中分享了公司在第二季中國市場收入貢獻達到81%,與該行觀點一致,即華虹受惠於中國半導體本地化需求,同時公司預期長遠有70%的收入來自中國市場,30%來自全球市場。另外,無錫九廠建設進展迅速,目標是年底前讓生產線準備好試產,並在明年首季開始釋放產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.